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Summary 
The EuroEVA project is the Portuguese component of the multicentre I-MOVE study and aims to obtain 
estimates of the seasonal and pandemic vaccine effectiveness during and after the influenza season.  
Since the 2008/2009 influenza season Portugal, along with other European countries, has implemented 
a common protocol using a case-control study design, where influenza-like illness cases which are 
laboratory confirmed as influenza (ILI+) are compared to a control group consisting of ILI patients which 
test negative for influenza (ILI-) (Case-control Test negative design).  
The results presented in this report relate to the EuroEVA 2011-2012 season and aim to estimate the 
seasonal influenza vaccine effectiveness for the age group 60+ years and in all age groups, using two 
approaches: Case-control Test negative design and Screening Method. 
 
Materials and Methods 
Test Negative Design 
ILI cases were identified among patients that presented ILI symptoms to a participating EuroEVA 
General Medical Practitioner (GP). On a weekly basis, each GP systematically selected ILI patients (two 
per week with less than 60 years and all ILI patients with 60 years and more) using the EU ILI case 
definition. Data on potential confounding factors and effect modifiers was collected using a 
standardized questionnaire which included information on socio-demographic variables (age, gender, 
education and co-inhabitants), previous (2010-11) influenza vaccination, chronic conditions and related 
hospitalizations, current smoking habits, belonging to GP list and number of consultations in the 
previous year. An ILI patient was considered vaccinated if he/she had received one dose of the 
2011/2012 trivalent influenza vaccine at least 14 days prior to onset of symptoms. VE was estimated as 
one minus the odds ratio of being vaccinated in cases versus controls adjusted for confounders by 
logistic regression. Potential confounders were investigated and included if: they changed crude OR 
estimate in at least 10% after adjustment by the Mantel-Haenszel method, were associated both to 
being a case (in the absence of the exposure factor) and to the seasonal vaccination. 
Screening Method 
ILI cases and ILI laboratory confirmed influenza cases were recruited in the context of the National I-
MOVE case-control study (EuroEVA). Vaccine coverage in the population was obtained from a sample 
of 1074 households stratified by region (homogeneous allocation) selected from a dual sample frame: 
random digit dialling mobile and landline phones (ECOS sample). Relevant information was collected by 
CATI (Computer Assisted Telephone interview) – one respondent by household (proxy for the rest of 
the household members). VE was estimated by comparing the proportion of vaccinated cases to the 
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vaccine coverage in the source population, using the Orenstein formula and the Farrington method to 
adjust for age group and target group for vaccination. 
 
Results 
In Portugal, a later beginning of the 2011/2012 influenza epidemic was observed, starting in week 
4/2012 and ending at week 12/2012. In this season both influenza B and A(H3) virus types were 
circulating, with predominance of the later. 
Test negative design 
From the 59 GP’s that accepted to participate in the study, 35 effectively participated in the study by 
selecting patients (which corresponds to a 59% participation rate). After excluding 79 ILI cases (for not 
adhering to the inclusion criteria) the final sample consisted on 273 ILI patients. Of the 134 cases which 
tested positive for influenza, 98.5% were positive for influenza A(H3) and the remaining for type B 
virus. The control group, consisting of 139 ILI patients who tested negative for influenza, was 
statistically different (p<0.05) from the ILI+ group in the following variables: 
• Clinical signs and symptoms: cough (higher in cases than in controls: 95.5% vs. 89.2%, 
respectively) and sore throat (more frequent in controls, 89.2%, than in cases ,75.4%); 
• Age: controls were older than cases (median age in controls was 52 yrs vs. 39 yrs in cases); 
• Any chronic disease: the prevalence of at least one chronic condition relevant for influenza 
vaccination was higher in controls (41.7% vs 29.1%); 
• Seasonal vaccine in 2010-11: controls were more often vaccinated against influenza in the last 
season than cases (30.2% vs. 14.4%); 
• Co-habitants: the median number of co-habitants was higher in cases (3 vs. 2).  
Considering all population, vaccine coverage (VC) in controls was 27.5% statistically higher than in cases 
(VC=13.4%). Similar results were obtained for the sub-group target for vaccination by the National 
Health Authorities (VC cases =24.6% and VC controls=46.1%, p=0.010). These results indicate that crude 
VE estimates was 59.2% (95% CI: 21.1%-79.4%) in the general population and 61.8% (95% CI: 15.5% 
;83.1%) in the target group for vaccination. After adjustment for co-inhabitants and month of onset of 
illness, VE adjusted estimates were 48.8% (95% CI: 0.0% ; 73.8%) and 51.6% (95% CI:-6.2%-77.9%) for 
the general population and for the target group, respectively. 
Screening Method 
The ECOS telephone survey was conducted during April 2012, and information was obtained from a 
total of 2395 individuals. According to the results, individuals were vaccinated from October 2011 
through January 2012, estimating a 16.4% (95% CI: 13.6-19.6) vaccine coverage (VC) in the population. 
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In the 60+ yrs age group, the VC was 37.3% (95% CI: 30.6-44.4) and for the individuals with chronic 
condition was 28.0% (95% CI: 23.0-33.7). The crude VE estimated with the Screening method for ILI+ as 
the outcome was 27.0% (95% CI: -19.9- 55.6) and -32.4% (95% CI: -77.7- 1.3) for ILI. Adjusted VE 
estimates varied from -90.4% (95% CI: -277.1- 3.9) (60+ yrs) to 6.1% (95% CI: -56.0- 43.4) (0-60 yrs) 
considering ILI as the outcome and from -58.6% (95% CI: -195.3- 14.8) to 56.9 (95% CI: -35.2- 86.3) for 
ILI positive outcomes (none were statistically significant). 
 
Conclusions 
Given the 3 years experience in conducting this study, logistical and implementation aspects were 
straightforward.  
The 2011-2012 season adjusted VE estimates were similar for the general population (48.8%) and for 
the target group (51.6%), although not statistical significant. When compared to the previous season, 
VE point estimate for the general population was lower (VE=58% in 2010-11), although the CI overlap. 
The population studied this year was older than in the last season. The time between onset of 
symptoms and swabbing, was also different with marginally, non significant, differences between cases 
and controls.  
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Introduction 
Influenza virus circulates every year causing epidemics that are generally benign for the human 
population, but causes more severe disease with high impacts on mortality and hospitalizations 1-3. This 
is particularly the case in specific population groups, such as the elderly and individuals with chronic 
conditions, which are at higher risk of becoming seriously affected.  
Vaccination has been one of the main measures to mitigate influenza impacts, its role in reducing the 
risk of developing the disease and the occurrence of associated complications being well recognized 4. In 
high-risk groups, influenza vaccine is recommended each year and, since the vaccine is also 
reformulated on a yearly basis, estimating influenza vaccine effectiveness (VE) in each season is of major 
importance to support public health decisions, both for the target group for vaccination and for the 
general population. 
In Portugal, during the 2005/2006 and 2006/2007 influenza seasons, the Instituto Nacional de Saúde 
Doutor Ricardo Jorge (National Institute of Health - INSA) conducted two pilot studies with a cohort 
design (EVA I and EVA II), and the results obtained suggested that the estimation of effectiveness of the 
anti-influenza vaccine should be based on multicentre studies involving several European countries5. 
Thus, since 2008-2009, INSA has been participating in the project I-MOVE (Influenza – Monitoring 
Vaccine Effectiveness in Europe), funded by the European Centre for Disease Preventions and Control 
(ECDC) trough its national component EuroEVA, (Efectividade da Vacina Antigripal na Europa). The I-
MOVE project aims at monitoring influenza vaccine effectiveness during influenza seasons and 
pandemics in the European Union, with the participation of several countries6  
The study conducted during the 2008-2009 season was essentially a pilot study to test if the case-
control design would be able to measure influenza vaccine effectiveness in-season and at the end of the 
season, among people aged 65 years and above, using several control groups. One of the controls used 
was the laboratory influenza-negative cases (test negative design) and this method has been used since 
then7.  
During the 2009-2010 influenza season, Portugal, Spain, Ireland, France, Italy, Hungary and Romania 
joined the I-MOVE multi-center case control study with a common protocol and with objective of 
estimating not only the seasonal influenza vaccine effectiveness but also the pandemic influenza VE, 
respectively in the elderly (65+) and in all age groups. In 2010-2011, 8 European countries participated in 
the multi-center case control study (Portugal, Spain, Italy, France, Poland, Hungary, Ireland and 
Romania) replicating the objectives and protocol used in 2009-10 season.  
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In the I-MOVE group, since 2009, 6 study sites (Portugal, Spain, England, Italy, France and Scotland) have 
been using the Screening method to estimate seasonal VE against medically attended influenza-like 
illness (ILI) cases and ILI laboratory confirmed influenza in primary care, general and ICU hospital wards. 
In Portugal, the Screening method was first used in the 2009/2010 season and this season it was once 
again used to estimate the 2011-12 seasonal influenza vaccine effectiveness against medically attended 
ILI cases and ILI laboratory confirmed influenza.  
This report describes the data collected and analyzed for the EuroEVA 2011-2012 season, with the 
objective of estimating seasonal influenza vaccine effectiveness, both in the 60 and plus years old and in 
all age groups. 
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Objectives  
Main objective 
The primary objective was to estimate influenza vaccine effectiveness among people of all ages and 
those aged 60 years and more in Portugal. 
Secondary objectives  
• To provide intra-seasonal VE estimates  
• To estimate according to risk group 
• To estimate VE according to influenza subtype  
8 
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Methods  
Study design  
In this study, two approaches were used (Figure 1):  
1) Test negative design: a case-control design approach in which laboratory confirmed influenza cases 
(ILI+) were compared to laboratory influenza-negative ILI patients (ILI-) ;  
2) Screening Method: compares the proportion of cases who are vaccinated with the proportion 
vaccinated in a comparable group in the population. Information on cases derived from the Test 
negative design. 
Study population and sampling design 
Test Negative Design 
The study population was composed of individuals of all ages and with no known contraindication for 
influenza vaccination. Sampling was performed in two steps (Figure 1):  
1. General practitioners (GPs) were contacted and selected from a list of medical general 
practitioners (GPs) that are, or were, members of the Rede Médicos Sentinela (Sentinel Network of 
Medical Practitioners). All GPs from this Portuguese Sentinel Network were invited to participate in 
the EuroEVA 2011-2012 study by ordinary mail and e-mail. The GPs were also asked to invite other 
GPs, not members of the Sentinel Network, to participate on the study, and these were contacted at a 
later stage. All GPs that participated on the previous EuroEVA 2010-2011 were invited. 
2. Each GP that accepted to participate was asked to select each week two ILI cases (EU ILI 
definition) under 60 years, and all ILI cases from individuals aged 60 years or more, from their weekly 
medical appointments (either they were enrolled, or not, in the GP’s list). 
Screening method 
In the Screening Method, the study population consisted of individuals of all ages with mobile and/or 
landline phones. The study was conducted as follows (Figure 1):  
1) Selection of households, stratified by Administrative region, with homogeneous allocation, using 
random digit dialing mobile and landline phones (ECOS sample8). 
2) One respondent in each household aged 18 or more (proxy information for the rest of the 
household members)  
10 
 
VC: vaccine coverage 
GP: General practitioner 
RT/PCR: real-time multiplex PCR 
Figure 1: Schematic flow of the test negative design and Screening method for estimating seasonal vaccine 
effectiveness (VE). 
Study period  
Test Negative Design 
In order to estimate seasonal VE, ILI cases were selected by GPs starting on 21st November 2011 (week 
46). As previously established in the scientific protocol, a period of 2 weeks with no positive cases for 
influenza, after the epidemic period, would determine the end of the study. Data collection ended at 
20th April 2012 (week 16), since from week 12 none of the enrolled ILI cases was positive for influenza. 
Screening method 
Data collection on community controls (ECOS sample) took place during March-April 2012. 
Outcome (Test Negative Design and Screening Method) 
For both methods, a confirmed case of influenza is defined as a person with an ILI with laboratory 
confirmation of infection with influenza B, A(H1N1), A(H3N2), or A(H1N1)pdm09, by one or more of the 
•Standardized questionnaire: one respondent by household 
(proxy for the rest of the household members).  
CASES (ILI+)
(positive for any 
influenza virus)
CONTROLS (ILI-)
(negative for any influenza 
virus)
2 ILI cases with 
less then 60 years
All  ILI cases with
60 years and above
Sample of GP’s
Systematic  selection
Data collection by the GP
1. Standardized questionnaire:
2. Nasopharyngeal swab
Laboratory analysis
(RT-PCR / Culture)
Mobile phones Landline phones
ECOS sample
Dual sample frame- random 
digit dialing sample
Data collection by  CATI 
(Computer Assisted Telephone interview)
VC  COMMUNITY 
CONTROLS
Data analysis
Vaccine coverage estimates weighted by 
sex and age of the Portuguese population
VC CASES (ILI+)
(positive for any 
influenza virus)
Screening MethodTest Negative Design
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following tests:  
1. real-time RT-PCR  
2. virus culture (MDCK-Siat1 cell line) 
 
For the Screening Method, influenza like illness cases were also considered as an outcome. 
Case definition  
Influenza-positive ILI cases were considered as Cases (for both methods) as well as ILI cases (for 
Screening Method only). An influenza like illness (ILI) was defined as an individual who consults a 
participating GP, presenting with a sudden onset of symptoms and at least one of the following four 
systemic symptoms (EU criteria)9: 
• fever or feverishness;  
• malaise;  
• headache;  
• myalgia; 
AND at least one of the following three respiratory symptoms:  
• cough;  
• sore throat;  
• shortness of breath. 
Laboratory confirmation  
Specimen’s collection 
The success of virus diagnosis largely depends on the quality of the specimen collection and on the 
conditions of transport and storage, before it is processed in the laboratory. 
Specimens were collected from ILI cases who attended their GP within 7 days after onset of clinical 
symptoms for influenza like illness.  
Nasopharyngeal swabs, or a combined nasopharyngeal and oropharyngeal swab were acceptable. 
Specimens were collected into a suitable transport medium. This procedure was conducted by the GP 
himself or by a nurse under his supervision. 
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Each sample was identified anonymously with the ILI case code, and the information related to the 
patient, demographic data, characteristics of the disease and the data concerning the confounding 
variables were recorded on the notification form. 
Storage, transport  
The specimens on viral transport medium were kept at 0 to 4ºC and transferred from the GP to the 
National Influenza Reference Laboratory by an express mail company within 24 hours, following the 
procedure already in place for the samples collected for routine surveillance of seasonal influenza. 
Laboratory Tests (RT-PCR / Culture)  
Laboratory confirmation of influenza infection was done using cell-tissue culture for influenza viruses 
and a real-time multiplex RT-PCR. 
Virus isolation is a very useful technique for the diagnosis of influenza infection allowing for further 
antigenic and genetic characterization of isolates, and also for vaccine preparation or drug-susceptibility 
testing. 
Isolates were characterized antigenically by haemagglutination inhibition tests (HAI), carried out using 
antisera and reference virus strains distributed by WHO Collaborating Center (London). Selected isolates 
were sent to the WHO Collaborating Center in London for further study. 
The rapid detection and typing of seasonal influenza viruses was performed by a multiplex “in house” 
real-time RT-PCR targeted to the matrix and nucleoprotein genes of influenza A and B, respectively. This 
is a powerful technique for the identification of influenza virus genomes even when they are present at 
very low levels. 
For influenza A subtyping, the Prodesse ProFAST+ Influenza A Subtyping assay (GEN-PROBE) was used. 
In order to identify the influenza B lineage (Yamagata/88 and Victoria/87), a multiplex “in house” real-
time RT-PCR was used. 
Strain characterization  
The phylogenetic analyses of the influenza virus isolates was performed by sequencing the coding region 
of the HA1 subunit of the haemagglutinin, for a subset of isolates from the beginning, the peak and the 
end of the season, representing 86.2% of the isolated strains, using the ClustalW Method for the 
multiple alignment and the Maximum Likelihood Method for the construction of the phylogenetic trees 
(MEGA Software). 
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Quality Control 
The National Influenza Reference Laboratory follows internal control procedures and also external 
quality control programs organized by the Global Influenza Surveillance and Response System (GISRS 
from WHO) and by the European Influenza Surveillance Network (EISN from ECDC). 
Case finding  
Procedures to select ILI cases 
ILI cases were identified among patients that presented ILI to a participating GP. For the purpose of 
estimating VE, GPs selected ILI cases of all ages and with 60 years or more. The ILI case could occur 
among GPs patient list or not, provided that an encounter patient/GP took place.  
ILI cases were recruited using the EU case definition, respecting the exclusion criteria (described below) 
and using a non-randomized systematic sampling method. This systematic sampling procedure consisted 
on the selection, by each GP, of the first two ILI cases with less than 60 years of each week and all ILI 
cases with 60 years or more. To avoid bias regarding the weekday, the first day of the week for each GP 
was randomly assign (e.g. for GP1 the week starts at Thursday, GP2 Tuesday, GP3 Monday, etc.). In this 
way, each GP had a different starting day of the week and received a SMS reminder the day before the 
start of his/her “week”.  
Case inclusion criteria  
Cases were eligible if they met the above case definition and accepted to participate. A written informed 
consent was requested to ILI cases after explaining the objectives of the study. 
Case exclusion criteria 
Cases were excluded if they: 
a) refused to participate in the study; 
b) were not eligible for influenza vaccination; 
c) were institutionalised; 
d) were unable to give informed consent or follow an interview in their native language because of 
aphasia, reduced consciousness, or other reasons. 
All excluded cases were registered in an appropriated form. 
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Control groups  
Test negative design (ILI influenza negative controls) 
Considering the Test negative design, Controls corresponded to individuals that presented ILI symptoms 
to a participating GP but were laboratory negative for influenza infection with A(H1N1), A(H3N2), B and 
A(H1N1)pdm09 viruses. 
As for Cases, Controls were systematically selected from the GP list or other, provided that an encounter 
patient/GP took place. The systematic sampling procedure was already described (for Cases). The 
exclusion criteria described for Cases were also applicable to Controls. Excluded controls were also 
registered in an appropriated form. 
Screening method (Community controls) 
Within the Screening Method, controls were selected from an already implemented vaccine coverage 
monitoring survey8. Between 1999 until the present season, the Department of Epidemiology of the 
National Institute of Health held yearly telephone surveys to the panel of families ECOS (Em Casa 
Observamos Saúde/ Observing Health at Home) with the aim of studying the influenza vaccine coverage 
in the Portuguese mainland population. 
Controls were selected from the ECOS sample, a population-based dual-frame sample of households 
with landline or mobile telephone. Data was collected via Computer Assisted Telephone Interview 
during March-April 2012. 
Exposure (vaccination)  
Target groups, vaccines in use 
The target groups for vaccination were all individuals belonging to a risk group (see below).  
During the 2011-2012 influenza season, seasonal vaccines were available at pharmacies and several 
brands were in use, namely:  
• Chiroflu, Novartis Vaccines and Diagnostics (non adjuvant); 
• Fluad, Novartis Vaccines and Diagnostics (adjuvant) - individuals with 65 or more years of age; 
• Fluarix GlaxoSmithKline (non adjuvant); 
• Influvac, Solvay Farma (non adjuvant); 
• Istivac, Sanofi Pasteur MSD (non adjuvant); 
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• Istivac Infantil, Sanofi Pasteur MSD (non adjuvant) – children with 6 to 35 months of age; 
• Intanza, Sanofi Pasteur MSD (non adjuvant) – individuals with 60 or more years of age. 
Vaccination campaign 
Seasonal vaccination campaign started on week 39 of 2011 (October 2011). 
Definition of vaccinated individual  
Seasonal vaccinated individuals were those that had taken the seasonal vaccine (one of the available 
brands) 14 days before the disease onset. 
Vaccine status ascertainment   
Test negative design: Inoculation with the 2011/2012 WHO approved influenza vaccine was ascertained 
by the GPs by consulting the patient’s record and confirming explicitly with the patient if the vaccine has 
been taken. 
If no data existed in the clinical record, patients were asked about vaccine inoculation status. Flu 
patients were asked if the inoculation was through a “shot”. The day and month of inoculation were also 
asked and recorded. 
Screening method: Vaccination status in the population was ascertained trough a questionnaire. In each 
household one individual with 18 or more years provided information on his/her vaccination status and 
on the rest of the household elements. Thus the terminology "percent of vaccinated" used in this report 
refers to individuals whose vaccination status was either self-reported or reported by proxy. For 
validation purposes, individuals were asked if the inoculation was through a “shot”.  
Risk groups 
Individuals were considered to belong to a risk group if in the GP records refer, or if the patient reports, 
they suffer from one of the underlying conditions included in the interview questionnaire. 
Risk groups10 individuals were all patients with at least one of the following underlying conditions: 
• Diabetes: if treated for insulin or non-insulin-dependent diabetes; 
• Cardiovascular disease (congenital heart disease, hypertensive heart disease, ischemic heart 
disease, chronic heart failure) 
• Chronic renal disease (chronic renal failure and nephrotic syndrome); 
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• Chronic hepatic disease (cirrhosis, biliar atresia and chronic hepatitis); 
• Obesity IMC>=30; 
• Chronic respiratory disease (asthma, chronic bronchitis, emphysema, bronchopulmonary 
dysplasia, cystic fibrosis, pneumoconiosis and pulmonary fibrosis) ; 
• Immunodeficiency congenital or acquired (conditions that suppress the immune function due to 
underlying disease and/or therapy, e.g. chemotherapy, HIV infection);  
• Neuromuscular disease. 
An individual was considered to belong to the target group for vaccination if he belongs to at least one 
of the following groups: 
a) suffer from at least one of the chronic condition listed above; 
b) age >=65 years; 
c) pregnancy in the second and third trimester; 
d) occupation (health professional and care taker); 
e) caregiver or cohabitant of children with less than 6 months with chronic conditions 
This season the influenza vaccination of the age group 60 to 64 years of age was recommended by the 
General Directorate of Health. 
Confounding factors and effect modifiers  
Test negative design 
Data on potential confounding factors and effect modifiers were collected using a standardised 
questionnaire. For Cases and Controls enrolled at GP practices, data was collected by a face-to-face 
interview.  
The questionnaire (annex B) was designed to collect information on risk groups plus the following 
variables: 
• Previous influenza vaccination (2010-2011): vaccination against seasonal influenza in the last 
season; 
• Patient is a health professional or care provider: the patient is a health professional/ care 
provider or caregiver or cohabitant of children with less than 6 months with chronic 
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conditions. These variables plus the information on chronic condition allowed us to identify 
patients belongs to the 2011-2012 seasonal vaccine target group, according to the General 
Directorate for Health recommendations10; 
• Severity: the severity of the underlying conditions was measured by the number of hospital 
admissions due to underlying conditions in the 12 months prior to inclusion in the study; 
• Smoking status: smoking history was collected and coded as either “never-smoker”, “former 
smoker” (stopped smoking at least one year before inclusion in the study) or “current 
smoker”; 
• Number of GP visits in previous year: in order to document and control for health seeking 
behavior the number of all GP visits in the 12 months before inclusion in the study.  
• Educational level: number of completed years of education; 
• Co-inhabitants: number of co-inhabitants was recorded considering the number of individuals 
that live in the same household with the patient (with or without family relations), excluding 
the patient; 
• Functional status: low functional status was defined as needing help to bath; 
• Antiviral administration: usage and type of antivirals was documented when applicable. 
Screening method 
Data was collected via Computer Assisted Telephone Interview (CATI). Information with interest for 
the current study included vaccine status, influenza-like illness symptoms from September until the 
day of the interview (yes or no) and declared presence/absence of chronic conditions. 
Sample size calculation  
The ILI cases sample size for the case control test negative design was set at 400. 
This value was calculated aiming to estimate a vaccine effectiveness of 50% with a lower bound of the 
95% confidence interval equal to 10%, assuming that the seasonal vaccine coverage in controls is 19% 
(all age groups) and that the proportion of ILI cases positive for influenza in the season was 45%. The 
expected vaccine effectiveness was set according to the 2010-2011 I-MOVE multicentre case control 
study. The assumed vaccine coverage in controls was the arithmetic average of vaccine coverage in 
the two previous seasons obtained by a telephone survey conducted in Portugal. The proportion of 
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positives for influenza was the average of the percentages observed in the two previous seasons in the 
Portuguese sentinel surveillance system. 
It should be stated that with this sample size, if the expected vaccine effectiveness is higher, 70% the 
lower bound of the confidence interval will be 40%. The calculation formula was adapted from 
Lemeshow, Hosmer and Klar (1988)11 who assumes a case control relation of 1:1 cases, in order to 
account for a chosen proportion of ILI cases positive for influenza, i.e. the case to control relation. 
The sample size of ILI cases was given by: 
 
  	
	 	
	 		 		

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Where: 
z1-α/2 is the standard Normal distribution 1-α/2 
percentile, 
p2 is the vaccination coverage in the controls,  
pI is the proportion ILI cases positive for influenza,  
ε is relative precision, 
  			. and VE is the expected vaccine 
effectiveness. 
 
During the 2010-2011 study, 288 ILI cases were recruited by 35 GP’s, which represents an average of 
approximately 8 ILI cases per GP. In this sense, to obtain the 400 ILI cases we the collaboration of 50 
GP’s. Considering the participation rate observed in last season (35/58=60%), our goal was to enroll 80 
GP’s to reach 50 participating GP’s to collect 400 ILI cases (180 influenza positive cases and 220 ILI test 
negative controls). 
Screening method 
For the Screening method the ECOS sample size is approximately 1000 household representing 3000 
individuals in all age groups. 
Data collection 
Test negative design  
Data on Cases and Controls was collected at the GP offices. GPs interviewed the patients using a 
standardized questionnaire (in annex B). Each participating GP filled in the questionnaire that included 
data on:  
1. study identification: country and GP; 
2.  case/control demographics; 
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3. ILI signs and symptoms;  
4. date of onset of ILI; 
5. date of swabbing; 
6. laboratory results (filled in after the laboratory result); 
7. patient is a health professional or care provider ; 
8. selected underlying chronic conditions (including diabetes, heart disease, chronic obstructing 
pulmonary disorder, renal diseases and immunodeficiencies); 
9. obesity (IMC>30); 
10. number of hospitalizations for selected underlying chronic diseases in the previous 12 months; 
11. total number of GP visits in the previous 12 months; 
12. smoking history; 
13. current season influenza vaccination including date and brand; 
14. influenza vaccination in the previous season; 
15. pregnancy status; 
16. functional status; 
17. antiviral administration 
Screening method 
Collected information for the community control group included: 
1.  individual code 
2. household code 
3. sex 
4. age 
5. ILI signs and symptoms; 
6. self reported underlying chronic conditions (including diabetes, heart disease, chronic 
obstructing pulmonary disorder, renal diseases, hepatic and immunodeficiencies). 
Transmission  
In the Test negative design, biological material (from the swab collection) and data from ILI cases were 
sent on a daily basis by mail to the Instituto Nacional de Saúde Doutor Ricardo Jorge where it was 
centrally treated. Laboratory results obtained by the National Influenza Virus Laboratory team were sent 
to the Department of Epidemiology team with ILI case code and influenza test results on a weekly basis. 
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In order to perform the pooled analysis of the data gathered by all the participating countries, data was 
also transmitted to Epiconcept, after data anonymization and coding according to the list of variables, 
definitions and coding previously provided to EpiConcept.  
Considering the Screening Method, the survey was conducted by an external company during one 
month. Database was sent to the Epidemiology Department where it was validated and analyzed. 
Entry  
In the Test negative design, final data entry was performed at Department of Epidemiology of the 
Instituto Nacional de Saúde Doutor Ricardo Jorge on a STATA SE 11 database by typing in the answers 
from the questionnaires and laboratory results. 
In the Screening method, data on the community controls were collected using CATI and entered in an 
Access data base. 
Validation  
Test negative design: Before data entry, a visual verification of missing and inconsistent values was 
done by the research team. After data entry a validation script was also run on the database.  
Validation procedures included verification of the presence of impossible values and of inconsistencies 
in and between variables. All missing or inconsistent values where clarified with the corresponding GP. 
Analysis  
Test negative design: Coding and categorization of variables  
All categorical variables were previously coded12 with exception of: 
• the age group was created from the variable age and categorized in four classes: 0-4; 5-14; 15-59 
and ≥60 years of age; 
• the indicator variable of the delay between the onset of disease and swab less than 3 days data 
was computed from the number of days between the onset and the swab; 
• the smoking status variable was recoded as 1- current smoker, and 0- former and never smoker; 
• the variables diabetes, cardiovascular disease, chronic cardiac failure, chronic renal disease, 
chronic hepatic disease, chronic respiratory disease and immunodeficiency were recoded into 1- 
any chronic disease (at least one of the previous list) and 0 – no chronic diseases. 
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The variables treated as numerical (discrete or continuous) were age, days between the onset of the 
symptoms and swab, number of previous hospitalizations due to the underlying chronic diseases in 
the last 12 months, number of education years, number of co-habitants and number of GP 
consultations in the last 12 months. 
Exposure to seasonal influenza vaccine variable: 
Vaccinated (coded 1)- ILI case has taken the seasonal vaccine 14 days before the disease onset;  
Not vaccinated (coded 0)-all others. 
Comparison of group’s characteristics 
In the Test negative design, Cases and Controls (ILI negative) were compared regarding the following 
variables: age, sex, pregnancy, morbid obesity, smoking status, diabetes, cardiovascular disease, heart 
failure, renal failure, chronic hepatic disease, immunodeficiency, any chronic condition, previous 
seasonal and pandemic vaccines (2009-2010), belong to target group, help for bathing, number of 
hospitalizations in the previous 12 months, years of education, patient belong to the GP list, number of 
GP consultation in the previous 12 months, number of co-habitants and ILI symptoms. 
Statistical comparisons were performed considering that the samples were independent. 
Association between variable Case/Control and all categorical variables was evaluated by the Chi-
squared test. If at least one of the table cells presented expected frequencies lower than 5, the Chi-
squared test was substitute by the Fisher’s Exact test. 
Comparisons of numerical variables between groups (Case/Control) were performed using the non 
parametric test of Mann-Whitney. 
Measure of effect  
Test negative design 
Vaccine effectiveness was computed as VE=1-OR (crude) and aVE=1-aOR (adjusted) where OR and aOR 
is respectively the crude and adjusted odds ratio of being vaccinated within Cases versus Controls. 
For the crude estimate, the exact 95% confidence interval of VE (OR) was obtained by the method 
described in Sahai H and Khurshid13. The confidence interval for the aVE was computed by the 
respective method of adjustment (non conditional Logistic Regression).  
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Screening method 
Vaccine effectiveness (crude and adjusted for age group and presence of at least one chronic disease) 
was also computed by comparing the proportion of vaccinated Cases (ILI+ and ILI) with the vaccine 
coverage estimated on the Community control group using the Screening method as described by 
Farrington 199314. 
Stratified analysis  
Due to the small sample size stratified analysis was not executed in the Test-negative design study.  
For the Screening method, 2011-12 seasonal VE was estimated for: the age groups <60 and ≥60 years of 
age and according to the presence of at least one chronic condition. 
Multivariable analysis  
The odds ratio of being vaccinated within Cases versus Controls was adjusted for possible confounders 
using non conditional logistic regression.  
Potential confounders were included in the model if they changed crude vaccine OR estimate in at least 
10% after adjustment by the Mantel-Haenszel (M-H) method, were associated to being a case (among 
the non-vaccinated) and were associated to the vaccine uptake. 
Restricted analysis  
For each outcome, case and controls were respectively restricted to the period from the first to the last 
ILI patient positive. 
Software used for data entry, statistical analysis.  
All the results were obtained using the package of statistical programs STATA/SE 1115. 
Logistical aspects 
Consent  
Each GP had the responsibility of obtaining written consent from ILI cases, after giving adequate 
information on the general study characteristics. 
Ethical approval  
The study protocol was submitted and authorized by the Comissão Nacional de Protecção de Dados 
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(National Committee for Data Protection) and submitted and approved by the Comissão de Ética (Ethics 
Committee) of Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P (annex A). 
Team  
Department of Epidemiology, Instituto Nacional de Saúde Doutor Ricardo Jorge  
Ausenda Machado, Baltazar Nunes (coordinator), Inês Batista 
National Influenza Virus Laboratory of the Department of Infectious Diseases, Instituto Nacional de 
Saúde Doutor Ricardo Jorge 
Patrícia Conde, Paulo Gonçalves, Pedro Pechirra, Inês João, Raquel Guiomar (co-coordinator) 
General Directorate of Health 
Isabel Falcão 
MS network and others GP 
(see Acknowledgments’ section) 
Supervision  
A supervising committee was established with participating members of the Direcção-Geral da Saúde 
(General Directorate of Health), INFARMED (National Authority of Medicines and Health Products), 
CEFAR/ANF (National Pharmacies Association) and APMGF (Portuguese Association of General 
Practitioners).  
Training  
After the selection procedure, to each one of the GPs that agreed to participate, a personal telephone 
contact was made by phone explaining the study and their participation. They also received the 
protocol, case definition questionnaires and laboratory swabbing procedures. 
The following items were discussed: 
• the design of the project;  
• the EU case definition; 
• the inclusion and exclusion criteria to select ILI cases and underlined that selection should be 
independent of vaccination status;  
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• definitions and concepts associated with each variable in the questionnaires and the way of 
answer or coding questions;  
• to collect nasopharingeal samples, and provide transportation to the National Influenza 
Reference laboratory in INSA;  
• to accept data quality checks on the quality of some selected issues. 
For these purposes several telephone calls have been made during the recruitment and development 
of the study. When necessary, some personal contacts or by e-mail have been made to clarify doubts. 
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Results  
Influenza 2011/2012 season  
Data collected through the National Influenza Surveillance Programme (Network of Sentinel General 
Practitioners- Rede Médicos Sentinela, Network of Emergency Units and National Laboratory Network 
for Influenza Diagnosis) reveals that the influenza activity in Portugal during the 2011-12 season was 
moderate-to-high, with a peak incidence during late-February through the beginning of March (Figure 
2). 
 
Figure 2: Distribution of ILI incidence rates, number of cases analyzed and number of viruses detected, by week 
during 2010-2011 and 2011-2012 influenza seasons (Data from the National Influenza Surveillance Programme). 
Duration  
The ILI incidence rate was above the baseline threshold from week 4/2012 through week 12/2012. By 
week 4, the ILI incidence rate began to rise quickly, peaked at week 10/2012 with the value of 137.7 
cases per 100 000 inhabitants, and decreased abruptly, falling below the baseline threshold from week 
13 onward. 
ILI incidence  
Comparing the epidemic period of 2011-2012 with the previous 2010-2011 season, the incidence rate 
peaked later during the 2011-2012 season (week 10/2012) than during 2010-2011 (week 52/2010), 
registering a maximum of 137.7 and 121.1 cases per 100 000 inhabitants, respectively.  
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ILI incidence rates were higher for the extreme age groups, i.e., in infants (age group 0-4 years) and for 
the elderly (≥65 years). This contrasts with the previous 2010/2011 season, when incidence rates were 
higher for the population aged 5-14 and 15-64 years (Figure 3). 
 
Figure 3: Distribution of ILI incidence rates by age group during 2010-2011 and 2011-2012 seasons. 
 
 
Virus circulation 
Influenza subtype A(H3) was the predominant (97.7%) influenza virus circulating during the 2011-12 
season. It was detected from week 51/2011 through week 18/2012, with a proportion of positive cases 
above 50% between weeks 3/2012 and 11/2012 (end of January through mid-March). Influenza viruses 
type B (Yamagata lineage) were detected sporadically during the second half of the season (weeks 7 
through 11). This contrasts with the 2010-11 season, when Influenza B/Victoria and A(H1)pdm09 viruses 
co-circulated. 
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Test Negative design 
Participating GP’s:  
After the selection procedure, 59 GP’s agreed to participate. About 59% (35) participated in the study by 
selecting, collecting swabs and data on Cases and Controls (Table 1). 
Table 1: Number of GPs that accepted to participate and those that selected at least one ILI patient. 
 
GPs currently participating in 
MS
1
 
GPs ex-participants in MS 
or others
1
 
Total 
All GPs accepting to 
participate 
26 33 59 
GPs reporting valid data 20 15 35 
1.
MS – “Médicos-Sentinela” network  
All participating GPs work in a Health Center of the National Health Service (Ministry of Health) and 
have a stable list of patients. GPs that accepted to participate in EuroEVA were distributed by all 5 
Administrative Regions and by 14 of the 18 Districts of mainland Portugal. GPs reporting ILI cases 
covered all 5 regions and 11 of the 18 Districts (Figure 4). 
a) 
 
b) 
 
Figure 4: Distribution of participating a) and effectively reporting b) GPs. 
Number of GP
No GP’s
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Description of participants  
A total of 352 ILI cases were selected by the participating GP’s during the study period. The final data set 
for analysis comprised 273 ILI cases. The flowchart of data inclusion/exclusion is presented in Figure 5.  
 
Figure 5: Flowchart of data inclusion/exclusion. 
Laboratory results  
Specimens were collected for virological analysis at the National Influenza Reference Laboratory, from 
the 352 cases reported, between weeks 46/2011 and 16/2012 (Figure 6). 
 
 
Figure 6: Weekly distribution of the 352 cases analyzed 
Data received352 -
Cases included in 
the analysis 
Data excluded
273
 Not adhering to EU ILI case definition (n=15)
 Interval between symptoms and swabbing > 
7 days (n=2)
 Controls selected before ISO week of 1st case 
and after last case (n=62)
79
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Laboratory analysis shows that only 40.1% of all ILI cases were associated with infection with influenza 
viruses, the majority of which of the A(H3) subtype (Figure 7). Influenza B(Yamagata) viruses were 
detected sporadically. 
 
Figure 7: Virological characterization of influenza like-illness cases. Influenza-positive results account for 40.1% of 
the total of cases analysed. 
 
As in the 2011/2012 influenza season, other respiratory viruses were also tested in the laboratory to 
further characterize the influenza-like syndrome. These included: respiratory syncytial virus types A and 
B, Rhinovirus, parainfluenza virus 1, 2 and 3, and adenovirus. The combined results are shown in Figure 
8. 
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Figure 8: Virological characterization of ILI cases. Combined laboratory results for influenza A and B, RSV A and B, 
rhinovirus, parainfluenza 1, 2 and 3, and adenovirus. 
One or more virus types were found in 52.3% of the ILI cases studied, the majority of which were 
influenza subtype A(H3) viruses (74.5%), followed by rhinoviruses (13.6%). RSV types A and B, and 
parainfluenza 1 and 3 were also found. 
Specimen inoculation into cell-tissue culture resulted in the isolation of 29 strains of influenza virus, 27 
influenza A(H3) and 2 influenza B (Yamagata) viruses. Although some antigenic variability was observed 
in influenza A(H3) viruses, they were all considered antigenically similar to the vaccine strain 
A/Perth/16/2009. The influenza B viruses were from a different lineage (Yamagata) comparing with the 
influenza B vaccine strain (Victoria lineage, strain B/Brisbane/60/2008). 
Genetic analysis based on the HA1 subunit of the hemagglutinin gene was performed on 23 influenza 
A(H3) viruses (14 isolates and  9 clinical samples) and 2 influenza B strains.   
Influenza A(H3) viruses clustered into 4 different genetic groups. Most of them (18 viruses) belong to 
clade 6 (represented by A/Iowa/19/2010). The remaining viruses clustered in clades 3 and 5 - two in 
subclade 3A, represented by A/Stockholm/18/ 2011, other two in subclade 3C, represented by the 
future vaccine strain A/Victoria/361/2011, and one virus in clade 5, represented by A/Perth/10/2010 
(figure X). Comparing to the vaccine strain A/Perth/16/2009, most of the 2011/2012 influenza A(H3) 
viruses presented 10 amino acid substitutions (nine of them located in hemagglutinin antigenic sites). 
Negative
168
47,7%
Influenza A(H3)
137
74,5%
A(H3)+Rhino
2
1,1%
Rhinovirus
25
13,6%
RSV A
6
3,3%
RSV B
4
2,2%Parainfluenza 1
7
3,8%
Parainfluenza 3
1
0,5%
Influenza 
B(Yamagata)
2
1,1%
Positive
184
52,3%
Total=352
31 
 
Figure 9: Phylogenetic tree of influenza A(H3) viruses based on the HA1 subunit. Bootstrapp values above 70 are 
shown. Viruses detected and characterised in this study are shown in red. Other reference and Portuguese strains 
are in black. The current and the future vaccine strains are highlighted in green and orange, respectively. - 
viruses detected in vaccinated individuals. 
The two influenza B strains detected are of the Yamagata lineage, in contrast with the influenza B 
vaccine strain (B/Brisbane/60/2008) which belongs to the Victoria lineage. From the genetic 
characterization, they group into different clades of the Yamagata lineage, one virus clustered in clade 2, 
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represented by B/Brisbane/3/2007 (a group of strains which had previously circulated) and another 
virus in clade 3 (a more recent group), represented by B/Bangladesh/3333/2007 (Figure 10). 
 
Figure 10: Phylogenetic tree of influenza B viruses based on the HA1 subunit. Bootstrapp values above 70 are 
shown. Viruses detected and characterised in this study are shown in red. Other reference and Portuguese strains 
are in black. The current and the future vaccine strains are highlighted in green and orange, respectively.  
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Description of Cases and Controls  
As referred, the data was restricted to the 273 ILI cases that fulfilled the inclusion/exclusion criteria. 
From these, 134 (49%) were positive for an influenza virus and were thus considered as cases in the 
analysis (132 were type AH3 and 2 were type B virus) and 139 (51%) tested negative for influenza and 
were thus considered as controls in the statistical analysis. For analysis purposes, the 134 were 
considered Cases and the 139 were considered as Controls. The comparison of cases and controls is 
presented in Tables 2 and 3. 
Considering the delay between onset and swab collection, no significant differences were found 
between cases and controls when comparing either the median number of days or the proportion of 
individuals with swabs within the first 3 days after symptom onset (Table 2). For the clinical symptoms 
(Table 2), statistically significant differences were found for cough, with cases presenting a higher 
frequency, and sore throat (controls referred this symptoms more often than cases).  
Table 2: Description of Cases and Control, from week 46 to week 12 during the 2011-2012 influenza season, 
according to time between the onset and swab, signs and symptoms, and treatment with antiviral 
 Cases Controls  p-value 
Time between onset and swab collection 
(days).  
   
median  2.0 2.0 0.115 
less than 72h,%  91.0 (134) 83.5 (139) 0.061 
Signs and symptoms, % (n)    
Fever 89.3 (131) 83.2 (131) 0.151 
Malaise  95.5 (133) 94.2 (139) 0.643 
Headache  85.1 (134) 78.3 (138) 0.147 
Myalgia  90.2 (132) 90.7 (139) 0.890 
Cough  95.5 (134) 89.2 (139) 0.050 
Sore throat  75.4 (134) 89.2 (139) 0.003 
Shortness of breath  16.5 (133) 24.6 (138) 0.100 
Antiviral use  0 (134) 0 (139) - 
(), number of valid answers; a Mann-Whitney test; b Fisher’s Exact test, c Chi-squared test; - Not computed 
 
In relation to demographic characteristics (Table 3), a significant difference was found in the age of the 
two groups (Cases were younger than Controls). For the remaining potential confounders (Table 3), the 
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following significant differences were identified when comparing cases to controls: 
 Controls presented a higher prevalence of any chronic condition (41.7% vs 29.1% for Cases);  
 Previous seasonal vaccine (2010-2011) was higher in Controls (30.2%) than in Cases (14.4%); 
 Cases had a higher median number of co-habitants (Controls: 2 vs Cases: 3).  
Table 3: Description of cases and controls, from week 46 to week 12 during 2011-2012 influenza season, 
according to demographic characteristics and potential confounders. 
 Cases Controls p-value 
Demographic characteristics     
Age, median  39 (129) 52 (130) <0.001 
0-4 yrs, %  0.8 0.7 
0.021 
5-14 yrs, %  14.2 7.9 
15-60 yrs, %  65.7 56.2 
≥60 yrs, %  19.4 35.3 
Sex, men %  47.0 (134) 40.3 (139) 0.262 
Potential confounders , %    
Belong to target group of vaccination 45.5 (134) 55.4 (139) 0.103 
Any chronic disease 29.1 (134) 41.7 (139) 0.029 
Seasonal vaccine 2010-11 14.4 (132) 30.2 (139) 0.002 
Smokers 14.2 (134) 13.0 (139) 0.767 
Help for bathing 2.4 (124) 3.0 (135) 0.788 
Belongs GP patient list 
63.4 (134) 68.4 (139) 0.392 
GP consultations last 12 mo, median  3 (130) 3 (139) 0.149 
Hospitalizations, median  0 (134) 0 (139) 0.149 
Years of education, median  7 (132) 6 (134) 0.716 
Co-inhabitants, median  3 (134) 2 (138) 0.001 
(), number of valid answers; a Mann-Whitney test; b Fisher’s Exact test, c Chi-squared test; - Not computed 
 
Vaccine coverage 
In the 2011-2012 season, the seasonal vaccine coverage in Controls was significantly higher (27.5%) than 
in Cases (ILI+) (13.4%) (Figure 11). Restricting the analysis to individuals belonging to target groups for 
vaccination, vaccine coverage in controls was 46.1% significantly higher than in cases (24.6%).  
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Figure 11: Comparison of vaccine coverage of Cases and Controls in all ILI+ cases and in the target group of 
vaccination. 
 
Vaccine effectiveness 
Considering the odds of being vaccinated in cases compared with controls, VE crude estimates were 
computed (Table 6). The 2011-2012 seasonal VE estimate was 59.2% (CI95%: 21.1%: 79.4%). 
Considering the target group for vaccination, the crude VE was 61.8% (CI95%: 15.5%; 83.1%). 
As mentioned in the Material and Methods section, in order to estimate adjusted VE, it was adopted a 
strategy that consisted in including only potential confounders that changed 2011-12 seasonal vaccine 
crude OR more than 10% after M-H adjustment, and were associated to being a case (among the non 
vaccinated) and were associated to the vaccine uptake. In Figure 12 it is presented the results of this 
analysis.  
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Figure 12: Seasonal vaccine 2011-12 OR change (%) after adjustment for potential confounding factors and 
association to ILI+ and vaccine uptake. 
 
As showed by Figure 12, the only factor that fulfills all the three criteria was the number of Co-
habitants (two categories: less than 3 co-habitants and 3 or more co-habitants). This result was used in 
order to obtain adjusted VE (Table 4). 
 
Table 4: Crude and adjusted seasonal 2011-12 vaccine effectiveness against influenza, estimates based on 
comparison of laboratory-confirmed influenza cases and control individuals (test-negative method), 2011-12 
influenza season, Portugal. 
 Crude  Adjusted*  
Population  VE CI95% VE CI95% 
All  59.2% 21.1% ; 79.4% 48.8% 0.0% ; 73.8% 
Target group of vaccination  61.8% 15.5% ; 83.1% 51.6% -6.2% ; 77.9% 
* Data used in the estimates from week 46 till week 12; VE estimates adjusted for number of co-habitants and month of onset of symptoms. 
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After the adjustment for confounders, via non conditional logistic regression, the VE estimates for all 
population decreased to 48.8% and to 51.6% in the target group of vaccination. None of these 
estimates were statistical significant. 
Screening method 
Vaccine coverage 
In Portugal, the vaccination campaign started on week 39 of 2011 and according to the results obtained 
with the yearly conducted dual-frame telephone survey, the vaccine coverage in 2011-2012 season was 
16.4%. 
Considering the population target group for vaccination, the vaccine coverage for the individuals with 
60 or more years was 37.3% (CI95%: 30.6-44.4) and 28.0% (CI95%: 23.0-33.7) for individuals with at 
least one chronic condition.  
Table 5: Influenza vaccine coverage (%) in the Portuguese population (All) and by age group and presence of a 
chronic condition. 
 Vaccine Coverage,% (95% CI) 
All  16.4  (13.6-19.6) 
0-59 yrs  9.3  (6.8,12.7) 
≥60  yrs  37.3  (30.6-44.4) 
No chronic  9.5  (7.1-12.6) 
Any chronic  28.0  (23.0-33.7) 
 
Considering the Screening method approach, and for All individuals, once again it was observed that 
the vaccine coverage in controls (from the community) was higher than the coverage in ILI+ (Table 6).  
 
Table 6: Influenza vaccine coverage (%) in the population and in ILI cases (total and ILI+). 
  Population ILI (v/n) ILI + (v/n) 
All  16.4 20.6 56/272 13.4 18/134 
0-59 yrs  9.3 8.6 17/197 6.5 7/108 
≥60 yrs  37.3 52.0 39/75 42.3 11/26 
No chronic  9.5 15.9 28/176 13.7 13/95 
Any chronic  28.0 29.2 28/96 12.8 5/39 
v – nr of vaccinated; n – nr of cases  
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However, after restringing the analysis to individuals with 60 and more years of age, vaccine coverage 
in the ILI+ and ILI was higher than the corresponding coverage in Controls. The only result on favor of 
the hypothesis of a protective effect of the vaccine was on the ILI+, where the vaccine coverage was 
smaller in cases than in corresponding population controls. 
Vaccine effectiveness 
Using the screening method approach, crude and adjusted VE were estimated (Table 7). According to 
these results, adjusted VE estimates varied from -90.4% (60+ yrs) to 6.1% (0-60 yrs) considering ILI as 
the outcome and from -58.6% to 56.9 for ILI positive outcomes (none were statistically significant). 
Crude and adjusted point estimates were higher considering only ILI positive for an influenza virus as 
the outcome measure, but estimative were very imprecise.   
 
Table 7: Crude and adjusted seasonal vaccine effectiveness for all ILI cases and for ILI positive for an influenza 
virus (ILI+).  
    Crude  Adjusted*  
Outcome    VE, % CI95% VE, % CI95% 
ILI+ 
All  27.0 -19.9; 55.6 4.2 -62.3; 43.4 
0-59 yrs  32.6 -44.9; 68.7 30.0 -52.2; 67.9 
≥60 yrs -23.5 -267.9; 58.6 -40.2 -323.6; 53.6 
No chronic  -51.2 -171.4; 15.8 -58.6 -195.3; 14.8 
Any chronic 62.3 -156.8; 91.4 56.9 -35.2; 86.3 
ILI 
All  -32.4 -77.7; 1.3 -35.2 -86.2; 1.8 
0-59 yrs  8.2 -50.9; 44.2 6.1 -56.0; 43.4 
≥60 yrs  -82.4 -257.4; 6.9 -90.4 -277.1; 3.9 
No chronic  -80.4 -170.2; -20.5 -77.6 -173.8; -15.3 
Any chronic  -5.7 -92.0; 41.9 -3.1 -93.5; 45.1 
* Adjusted for confounding (age group and presence of chronic diseases) using the Farrington method 
Estimates based on comparison of laboratory-confirmed influenza case subjects and community controls, influenza season 
2011-12. 
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Discussion 
Seasonal 2011-2012 Vaccine effectiveness against laboratory confirmed influenza cases and 
Influenza-like illness cases as outcome 
Laboratory confirmed influenza 
According to the results obtained using the test negative design data of the EuroEVA study, the 2011-
2012 adjusted VE against medical attended laboratory confirmed influenza was 48.8% in the general 
population and 51.6% in the target group for vaccination. The results obtained in the target group are 
consistent with the 2011-2012 VE estimated within the I-MOVE multicentric study16 (43%; 95% CI: -0.4 
to 67.7) and with early estimates obtained in Spain17 (55%; 95% CI: 3 - 79). 
Comparing with results obtained with the Screening Method, VE estimates were considerably lower: 4% 
for the general population and -40% for individuals with 60 and more years of age. The only similar 
value was the one estimated for the individuals with at least one chronic condition, 56.9% (CI95%: -35.2- 
86.3. It should be stated that none of these estimates were statistical significant.  
Since the two methods do not agree on the protective/ non protective effect of the 2011-12 influenza 
vaccine, some considerations should be done regarding these two estimates. According to Oreinstein et 
al. (1985)18, the Screening method only provides a rough guide of the VE point estimates and for this 
reason it should not be relied upon for precise estimates. For that reason, the Test Negative Design VE 
estimates should be more reliable. Nevertheless, it should be stated that the Screening method did 
detect a decrease in VE point estimate and thus, for monitoring purposes (providing that biases remain 
constant between seasons) the Screening method may be used for monitoring changes in VE over time 
and is useful for routine monitoring of VE18. 
Within EuroEVA results, for the previous season 2010-11, VE from both methods were similar (59% Test 
Negative Design- TND, 63% Screening) 19. For the 2011-2012 season, however, both VE estimative 
indicate different vaccine effect against ILI positive for influenza viruses. As reported for that season, 
the consistency between results was due to the similarity of vaccine coverage estimates between ILI 
laboratory influenza negative controls and the community controls from population sample ECOS19. 
This season, vaccine coverage in these two groups were different (Community controls ECOS 16.4%; 
TND controls 27.5%). The increase of the median age of TND controls this season may have played an 
important role in the discrepancy.  
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When compared to the last season, VE point estimate for the general population was lower in 2010-11 
(VE=58% in 2010-11). However overlapping confidence intervals and the laboratory results may bring 
forward a possible explanation for this VE decrease.  
Laboratory results, from the phylogenetic analysis by sequencing the coding region of the HA1 subunit 
of the haemagglutinin gene, showed that the majority of the influenza A(H3) viruses detected in 
vaccinated individuals grouped into clade 6 are represented by A/Iowa/19/2010 strain. Compared to the 
vaccine strain A/Perth/16/2009, most of the 2011/2012 influenza A(H3) viruses presented 10 amino acid 
substitutions (nine of them located in haemagglutinin antigenic sites). However, all strains were 
antigenically similar to the vaccine strain.  
Influenza-like illness outcome 
Seasonal 2011-12 adjusted VE against influenza-like illness was -35.2% (CI95%: -86.2; 1.8) for the general 
population, and in the target population it varied between -90.4% (C95%:-277.1; 3.9) and -3.1% (CI95%: 
-93.5; 45.1), for the population with 60 and more yrs and with chronic condition, respectively. These VE 
estimates were only obtained through the Screening method, thus there is no comparison available 
within EuroEVA study.   
Considering the Screening method, VE for ILI was lower than VE for ILI+, a result which was expected 
since ILI case is a less specific measure then laboratory confirmed influenza case. 
Participation rate  
Overall 59 GP’s were enrolled in EuroEVA 2011-12. Considering the sample size dimension20 and the 
recommendations from season 2010-2011, the number of GP needed for the selection was 80 which 
means that, this season, the recruitment process was still short of the intended. Different approaches 
were tried to encourage participation, such as using informal contacts or previous mailing lists, but with 
limited success.  
Participation rates remained at 59%, even though additional efforts to stimulate case collection were 
implemented, such as issuing a monthly newsletter (4 were issued) and weekly data validation by 
mobile phone. 
Although the number of GP’s planned was not achieved, the total number of ILI cases recruited was 
higher than would be expected with 35 GP’s reporting ILI cases. In the planning phase the expected 
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number of ILI cases per GP was 6, given that we received 352 ILI cases the average number of ILI cases 
effectively recruited by GP was 10. 
Participating GPs are volunteers for EuroEVA as they are for participating on the MS network. Therefore 
they do not represent the total group of GPs working in health centers, in Mainland Portugal. 
ILI cases selection 
As in the previous studies, the EU ILI definition was used for the identification of ILI cases. From all the 
ILI cases enrolled with complete biological and clinical information, only 15 did not meet the EU ILI case 
definition (comparing with 17 last season). This result indicates that a correct ILI case selection has been 
maintained in the EuroEVA study. In part, this may be due to the long experience of most GPs in 
participating in the EuroEVA study.  
A systematic ILI case selection scheme was again used this season, consisting of randomly attributing a 
different day of week to each GP (from Monday to Thursday) in which they would start selecting ILI 
cases, keeping the restriction of selecting only two ILI cases per week from individuals with less than 60 
years of age, and no limit to the number of 60+ ILI cases selected. This strategy was intended to increase 
the previously observed low proportion of ILI cases with 65+ years of age, but proved relatively 
successful in practice. 
Controls 
The ILI influenza negative cases and the community sample were once again used as controls. The ILI 
influenza negative controls were particularly interesting since they were obtained directly from the 
routine surveillance system, just adding a number of variables to be used mainly in stratified analysis, 
effect modification and confounding. 
Also of substantial interest is the community control group selected from the Portuguese general 
population directly from an independent routine source that is easily accessed since is a national routine 
system to estimate seasonal vaccine coverage.  
As stated before, no consistency was obtained between both methods this season and a probable 
explanation for this was the difference found in both controls groups. This result highlights one of the 
limitations of the Screening method. 
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In order to have a proper use of this method, coverage estimates should match the population from 
which the cases came21. Because the source population used is not the GP’s catchment area population 
but a national sample of households with mobile and landline phone, controls from both methods 
differed (at least concerning the age). 
Also a limitation of the Screening method, as used here, is the fact that the vaccine coverage used was 
assumed as known. However, it was also obtained from a population sample, so the variance of this 
estimate should be included in the 95% confidence interval VE estimate. This correction was not done 
because the Farrington method does not allow it. Further developments are needed to include this 
information in the VE estimate. 
Vaccination status 
Considering the test negative design, the vaccination status was ascertained with the same approach for 
cases and controls. Along the data entered in the patient medical record, GPs were asked to confirm the 
inoculation of vaccine with the patient, and register the brand name of the vaccine. Complementarily, 
the GPs would also verify the mode of inoculation. It is improbable that GPs used different 
ascertainment criteria, especially between their own ILI cases and controls. 
Information bias 
Data on variables used to characterize cases and controls were collected by direct interview conducted 
by the participating GP. As the questionnaires were similar for both cases and controls, and the GP’s 
were only informed of the laboratory result at a later stage, it is unlikely that GPs collected data 
differently in cases and controls. 
Regarding the Screening method, it must be cleared the fact that information on the vaccine uptake and 
presence of chronic condition was self-reported for respondents or given by proxy for the remaining 
household members. This could introduce bias since information on vaccination status differs from 
cases (collected and validated by the GP) and controls (self reported). In order to decrease bias, only 
controls that referred inoculation was made through a shot were considered as vaccinated. 
Bias associated to the sensitivity of the case definition used in EuroEVA 
As declared before, cases were selected according to EU ILI definition. This EU ILI criterion consists in a 
very stringent combination of symptoms. It should be taken into consideration that, by using this kind of 
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case definition, some ILI cases with milder symptoms may be discarded in the selection and this could 
introduce bias in our VE estimate. For instance, if vaccination induces the occurrence of true cases of 
influenza with a smaller number and “mild” symptoms/signs, GPs would have a higher probability of 
failing to select such “mild”, but true cases, for lab confirmation, resulting in less sensitivity to select 
positive cases that had been vaccinated. This fact would underestimate vaccine coverage in cases and 
over estimate VE. Even though the possibility of this bias is recognized, is not possible to estimate its 
dimension in the context of EuroEVA.  
Effects of adjustment 
In order to obtain adjusted VE point estimates, potential confounders were selected using a three step 
criteria that included: change more than 10% the crude seasonal vaccine OR, be associated to being a 
case (among non vaccinated) and to the vaccine uptake. With this kind of approach, it was possible to 
identify proper confounders and reduce an over adjustment. After this procedure, the number of co-
habitants was the only identified confounder (positive effect).  
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Conclusion 
Considering the Test negative design, the 2011-2012 seasonal adjusted VE estimates were similar 
between the general population (48.8%) and target group (51.6%), but not statistical significant. When 
compared to last season, VE point estimates for the general population were lower (VE=58% in 2010-11) 
but with overlapping confidence intervals. 
The Screening method provided lower estimates of the VE, 4% for the general population and -40% for 
individuals with 60 and more years. However, due to method limitations, these values should not be 
relied upon for exact estimate of vaccine effectiveness. 
Laboratory results show the increasing antigenic and genetic variability among the influenza A(H3) 
studied during the 2011/2012 season, and also identify influenza B viruses circulating of a lineage 
different from that included in the 2011/2012 anti-influenza vaccine. These facts, alone or combined, 
may provide some explanation to the low/moderate VE estimates.  
The 3-year experience in conducting this study was certainly a major contribute in streamlining the 
logistic aspects of this project. 
Even though the total number of ILI cases recruited was higher than expected, the sample size for the 
60+ yrs group does impose some limits in obtaining a more precise VE estimate for this age group.  
As concluded in previous studies, these results still make evident the need for pooling data from a 
network of VE studies with a common protocol, such as I-MOVE. 
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O estudo visa estimar a efectividade da vacina contra a gripe sazonal, em indivíduos de todas as 
idades com particular enfoque em indivíduos com idade igual ou superior a 60 anos.  
Este estudo tem um delineamento caso-controlo e terá início em 14 de Novembro de 2011. 
Gostaríamos que seleccionasse casos de síndroma gripal com idade inferior a 60 anos (até 2 casos por 
semana) bem como TODOS os casos de síndroma gripal com 60 e mais anos. 
A selecção de casos começa à 2ª feira, com duração até ao final da época gripal, i.e., semana 20 de 
2012.  
 
AVALIAÇÃO DA EFECTIVIDADE DA VACINA DA GRIPE SAZONAL 
 
MÉTODO 
 
Pretende-se verificar se há diferenças na percentagem de vacinados, entre os 2 grupos seguintes: 
 
1. casos de síndroma gripal com resultado laboratorial positivo para gripe; 
2. casos de síndroma gripal com resultado laboratorial negativo para gripe.  
 
Para a Vigilância da Síndrome Gripal, os exames laboratoriais a efectuar consistem no isolamento e na 
detecção do RNA do vírus da gripe. Para o isolamento do vírus e a detecção do RNA viral é necessário: 
 
• Um exsudado da nasofarínge colhido durante os primeiros 5 dias de evolução da doença (de 
preferência até ao 2º ou 3º dia) em zaragatoa cedida pelo INSA e enviada rapidamente pela 
Alfaloc, Transportes Expresso. 
 
 
 
 
 
NOTA PARA MÉDICOS-SENTINELA 
Se é Médico-Sentinela e já participa no programa de vigilância clínica e laboratorial da gripe, continue 
a fazê-lo como habitualmente. A única diferença é que, para este estudo, em 2 casos de sindroma 
gripal por semana com idade inferior a 60 anos e para TODOS os casos de sindroma gripal com 60 e 
mais anos, terá de substituir a folha de preenchimento a que está habituado pela folha do 
questionário. 
 
PROCEDIMENTOS 
A cada médico participante será fornecido um caderno com instruções, 16 questionários, 40 folhas 
para o consentimento informado (a serem preenchidas em duplicado por cada caso), e uma folha 
para a recusa/exclusão de casos para o estudo (folha branca). O questionário deverá ser preenchido 
57 
sempre que identificar um caso de sindroma gripal na sua lista de utentes ou fora dela.  
Note que os questionários estão pré-codificados com o código de caso, no canto superior direito, o 
que permite a respectiva identificação. Por favor registe, no cabeçalho do questionário, os dados de 
identificação pessoal de cada caso (Nome e Nº SNS ou do Processo Clínico). 
Cada médico receberá também um “kit” para colheita de exsudado nasofaríngeo que deverá também 
ser identificado com o código de caso (o mesmo que se encontra no canto superior direito do 
questionário). Para tal, basta destacar a etiqueta como código de caso que se encontra no canto 
inferior direito do questionário e cole na zaragatoa. 
 
1.  Selecção dos casos de síndroma gripal 
 
Seleccione, na sua lista de utentes, ou fora dela, doentes com síndroma gripal. Deve identificar 2 casos 
de sindroma gripal com idade inferior a 60 anos e TODOS os casos de sindroma gripal com idade 
igual ou superior a 60 anos, a partir de 2ª feira inclusive, até ao final da época de gripe, i.e. finais de 
Abril. Se não identificar nenhum caso no dia da semana referido, tente nos dias seguintes, até 
conseguir. Os casos podem ser seleccionados onde for mais conveniente para si, i.e., em consultas, 
serviços de urgência, no domicílio, atendimentos complementares, etc. 
 
A definição de sindroma gripal é a recomendada pelo Centro Europeu de Prevenção e Controlo de 
Doenças (ECDC):  
 
Grupo A + pelo menos 1 sinal ou sintoma do grupo B + pelo menos 1 sinal ou sintoma do grupo C 
 
 
Grupo A 
Início súbito (obrigatório) 
Grupo B 
• Febre ou febrícula  
• Mal-estar, debilidade, prostração 
• Cefaleia  
• Mialgias, dores generalizadas 
Grupo C 
• Tosse  
• Dor de garganta, inflamação da mucosa nasal e faríngea, sem sinais respiratórios relevantes  
• Dificuldade respiratória  
Se o doente estiver a viver num lar ou residência para idosos ou tiver contra-indicação para a toma 
da vacina sazonal, exclua-o do estudo, preencha a folha branca de recusa/exclusão e identifique 
outro caso de sindroma gripal. 
O doente deve tomar conhecimento de que vai ser incluído neste estudo e concordar com essa 
participação, assinando em duplicado a folha de consentimento informado. 
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2. Colheita de dados  
 
Preencha o questionário (folha amarela, frente e verso) que descreve a sindroma gripal (data de início 
dos sintomas, sintomas e sinais presentes, estado vacinal em 2011/12 e no ano anterior, toma de 
antivirais e estado de saúde ou doença do indivíduo). Assinale com um X sobre o espaço ou sobre a 
letra adequada.  
Por favor, confirme directamente com o doente ou processo clínico as respostas que vai dar. 
 
Destaque o questionário pelo picotado, sem o cabeçalho com a identificação do utente e envie-o 
juntamente com o exsudado nasofaríngeo cuja colheita se descreve a seguir. 
 
O cabeçalho com a identificação do utente deve ficar no seu caderno de questionários para futura 
consulta, caso haja alguma dúvida sobre o caso enviado. 
 
3.  Colheita de exsudado da nasofarínge  
 
a) Recolha um exsudado nasofaríngeo de acordo com as instruções seguintes: 
1. Introduza a zaragatoa na narina (direita e esquerda) paralelamente ao palato e deixe nessa 
posição alguns segundos de forma a absorver as secreções; 
2. Introduza um pouco mais fundo na mucosa nasal (aproximadamente 2 a 3 centímetros no 
adulto e até o doente lacrimejar) e rode ligeiramente a zaragatoa; 
3. Retire a tampa do tubo de transporte e introduza a zaragatoa para que esta entre em 
contacto com a esponja existente no fundo do tubo; 
4. Pressione fortemente a parte inferior do tubo de modo a que o meio de transporte que 
embebe a esponja molhe o algodão da zaragatoa; 
b) Identifique o tubo com o código de caso (destaque a etiqueta e cole na zaragatoa). 
c) A amostra biológica deve ser conservada entre 4 a 8ºC até à recolha pela transportadora, para 
envio ao laboratório. 
d) O tubo deve ser acondicionado individualmente, vedando a sua tampa com parafilm (segue com 
o restante material) e introduzindo-o num saco de plástico devidamente fechado. Este saco 
deve ser introduzido num envelope almofadado que, por sua vez, deve ser introduzido numa 
das bolsas plásticas (alfapack) fornecidas. 
 
4. Envio do questionário e zaragatoa para o laboratório 
 
A rapidez no envio das zaragatoas ao laboratório constitui um dos aspectos de maior relevância para a 
obtenção de resultados válidos no diagnóstico. Neste sentido, solicita-se que sejam enviados o mais 
brevemente possível.  
Os pedidos de recolha à empresa transportadora poderão ser efectuados por telefone ou por e-mail, 
até às 12h00, de Segunda a Quinta-feira.  
• Por telefone: o requerente deverá ligar para a linha 707 212 707 e solicitar a recolha de 
encomenda no âmbito do Programa de Vigilância da Gripe (a chamada será encaminhada para 
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um serviço de transporte específico para este Programa) identificando a conta do INSA número 
6226 e o seu código de Médico (na primeira página destas instruções) seguido da localidade da 
recolha. 
• Por e-mail: enviar o pedido de recolha para www.alfaloc.pt indicando a conta do INSA número 
6226 e o seu código de Médico (na primeira página destas instruções) seguido da localidade da 
recolha. O responsável da Alfaloc pelo registo das recolhas acusará a recepção deste e-mail no 
prazo máximo de 15 minutos; se o requerente não receber a confirmação da recepção do 
pedido de recolha neste prazo, deverá contactar o serviço de clientes pela linha 707 212 707. 
Serão disponibilizadas, nos locais de recolha, guias de transporte pré-impressas com informação do 
nome e morada do expedidor e do destinatário (o INSA).  
Para qualquer informação adicional, por favor contactar o Laboratório Nacional de Referência para o 
Vírus da Gripe do Instituto Nacional de Saúde Dr. Ricardo Jorge, Av. Padre Cruz, 1649-016 Lisboa, Tel: 
217526455 ou 217519216. 
 
  
Seleccione o doente com sindroma gripal
(2 com idade  <60 anos e TODOS com 60 
ou mais anos)
Segunda - Feira
Recolha o exsudado naso-faríngeo 
(zaragatoa)
Consentimento informado
(escrito)
Preencha o questionário
(coloque um X sobre o espaço ou letra adequada)
Contacte a empresa de transporte Alfaloc e 
envie o questionário e zaragatoa para o 
INSA
Obrigado!
O doente tem  contra-
indicação para vacina da 
gripe?
O doente vive num lar 
ou residência para 
idosos?
O doente aceita 
participar no 
estudo?
 O doente cumpre critérios de 
participação 
S
N
Registo do motivo da 
exclusão (folha branca)
Registo do motivo da 
recusa (folha branca)
Registo do motivo da 
exclusão (folha branca)
S
S
Identifique o tubo com a etiqueta que 
consta do questionário
(acondicionar de acordo com ponto 3 das instruções) 
N
N
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